A heart-rate-reducing medication reduces the risk of heart failure and cardiac fibrosis
Key points
- The findings of a Montreal Heart Institute (MHI) study published in the scientific journal Cardiology suggest that ivabradine, a heart rate reduction medication, is also effective in reducing the risk of diastolic heart failure (left ventricular insufficiency) and cardiac fibrosis.
- The benefits of slower heart rate on mortality and morbidity associated with cardiovascular disease no longer need to be demonstrated.
- The study was conducted on rabbits given a standard diet, a cholesterol-enriched diet or a cholesterol-enriched diet with ivabradine.
- Jean-Claude Tardif, Director of the MHI Research Centre and professor of medicine at the Université de Montréal, the results are both interesting and encouraging.
The findings of a Montreal Heart Institute (MHI) study published in the scientific journal Cardiology suggest that ivabradine, a heart rate reduction medication, is also effective in reducing the risk of diastolic heart failure (left ventricular insufficiency) and cardiac fibrosis.
The benefits of slower heart rate on mortality and morbidity associated with cardiovascular disease no longer need to be demonstrated. In this study, titled "Heart Rate Reduction by Ivabradine Reduces Diastolic Dysfunction and Cardiac Fibrosis," researchers sought to determine the effectiveness of ivabradine in treating diastolic dysfunction of the left ventricle, a condition affecting 40% of people with heart failure.
The study was conducted on rabbits given a standard diet, a cholesterol-enriched diet or a cholesterol-enriched diet with ivabradine. It revealed that as well as improving the myocardial performance index, ivabradine greatly improved left ventricular diastolic dysfunction in animals receiving a cholesterol-enriched diet. Ivabradine also reduced fibrosis of the heart chambers.
According to Dr. Jean-Claude Tardif, Director of the MHI Research Centre and professor of medicine at the Université de Montréal, the results are both interesting and encouraging. "The effectiveness of ivabradine in treating angina pectoris is now well known. However, few treatments are available to patients with diastolic heart failure. The beneficial effects of ivabradine demonstrated in laboratory suggest that this course of treatment should be further investigated." Clinical studies with subjects are expected to follow.
###
Contact: Julie Chevrette
[email protected]
514-376-3330 x2641
Montreal Heart Institute
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Heart & Blood Vessels →
NewsHeart rate recovery predicts clinical worsening in pulmonary hypertension
Heart rate recovery at one minute after a six-minute walking distance (6MWD) test is highly predictive of clinical worsening and time to clinical worsening in patients with idiopathic pulmonary arterial hypertension…
19 November 2011
NewsCardiac rehabilitation improves heart rate recovery, boosts survival
For the first time, researchers have discovered cardiac rehabilitation can train the heart to quickly return to its normal rate after exercise. In a study reported in Circulation: Journal of the American Heart…
28 September 2011
NewsStents may reduce heart attacks by delivering downstream medication
Researchers at Cleveland Clinic have discovered that cardiac patients receiving medicated stents – a procedure that occurs often when blood vessels are blocked - have a lower likelihood of suffering heart attacks or…
